FDA 510(k)
FDA class 2
Unknown
🇺🇸 United States
MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets):a Hybridization-Capture Based Next Generation Sequencing Assay
K Number: DEN170058
·
Decision Nov 15, 2017
Classifications
1
FEI Numbers
5
Registration Numbers
5
Same Product Code
7
Applicant Total
1
Review Days
51
Research this 510(k) in seconds
The Research Assistant summarizes clearance history, predicates and product-code trends — and cites every record.
Free to try · every answer cites its records
Basic Information
- Device Name
- MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets):a Hybridization-Capture Based Next Generation Sequencing Assay
- K Number
- DEN170058
- Device Class
- FDA class 2
- Clearance Type
- Direct
- Regulation Number
- 866.6080
- Medical Specialty
- Pathology
- Decision
- Unknown
- Applicant
- Memorial Sloan-Kettering Cancer Center
- Date Received
- September 25, 2017
- Decision Date
- November 15, 2017
- Product Code
- PZM
- Advisory Committee
- Pathology
- Review Advisory Committee
- PA
- Third Party
- N
Classifications
This FDA 510(k) entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| PZM | Next Generation Sequencing Based Tumor Profiling Test | FDA class 2 | Pathology |
Similar 510(k) Clearances
Other 510(k) clearances with the same product code (PZM), ordered by most recent decision date.
CellDx-Tissue
FDA 510(k)
FDA Class 2
·Pathology
xR IVD
FDA 510(k)
FDA Class 2
·Pathology
GENESEEQPRIME NGS Tumor Profiling Assay (FFPE) (GS6005)
FDA 510(k)
FDA Class 2
·Pathology
ACTOnco, ACTOnco IVD
FDA 510(k)
FDA Class 2
·Pathology
NYU Langone Genome PACT (Genome Profiling of Actionable Cancer Targets)
FDA 510(k)
FDA Class 2
·Pathology
PGDx elio tissue complete
FDA 510(k)
FDA Class 2
·Pathology